When we published the first edition of A Decisionmaker's Guide to Competing Health Evidence last month, we set out to do something simple: help busy decisionmakers understand why smart people citing the same evidence often reach different conclusions. The response exceeded our expectations. Congressional offices read it and shared it. Stakeholders engaged with it seriously. And we learned things that are already making the series better.
Here is what we took away from the first edition, and what you can expect going forward.
The goal of this series
Each edition of A Decisionmaker's Guide takes a live health policy debate, maps the competing claims, and gives readers the tools to evaluate the evidence themselves. We do not take positions. We do not advocate for or against any proposal. What we do is explain why the debate looks the way it does, and what the research actually shows.
That independence is the whole point. It is also a responsibility. When you are asking people to trust your analysis, you have to be rigorous about getting things right, transparent when you fall short, and firm when outside pressure pushes you to adjust what you got right.
What we updated in edition one
After publication, we received substantive feedback that identified several factual details our analysis had missed or understated. We reviewed each one carefully. Where the feedback identified genuine gaps, we updated the guide. The changes include:
- Adding detail on the proposal's growth cap provision, which limits annual hospital price increases and is, in many ways, the more consequential feature of the policy over time
- Clarifying that the hospital price cap is a composite across services, not a per-service limit, which changes the analysis of hospital cross-subsidization
- Correcting our characterization of the prior authorization provisions, which retain pre-review for high-cost services rather than eliminating it entirely
- Tightening our description of state-level price cap activity to reflect what has actually moved forward
The updated edition is available now at the same link as the original. A note at the top explains what changed and why. Our overall assessment is unchanged.
What we are building into our process going forward
The feedback we received pointed to a process question more than a content one: how do we catch factual details like these before publication? We are making two changes starting with the next edition.
- Pre-publication factual review: We will give the primary subject of our analysis a brief window before publication to flag factual errors. This is not an opportunity to shape our framing or conclusions. We retain full editorial control. But it helps ensure we have the details right.
- Independent accuracy check: We will ask a neutral subject matter expert to do a quick read on near-final drafts. Not peer review. Just a gut check from someone with no stake in the outcome.
We are also formalizing a 30-day correction window. Factual corrections submitted within 30 days of publication will be reviewed and, where warranted, incorporated into an updated edition with a clear note explaining what changed. After 30 days, editions stand as the published record of the evidence as it existed at the time of release.
What we will not change
Our stakeholder sections map the positions of major actors in a debate. They are not endorsements of those positions. We describe what each group argues so readers know the terrain before they engage with the evidence. Going forward we will make that clearer with an explicit disclaimer in each edition.
We will also hold firm on our framing and conclusions when we believe they are accurate. Getting the analysis right means correcting genuine errors. It also means not adjusting our interpretation of the evidence because a stakeholder would prefer a different one. Both matter equally to the credibility of this series.
What is coming next
Our May edition examines the 340B drug pricing program, one of the most contested and least understood programs in health policy. At $81 billion in discounted drug purchases in 2024, it is now larger than the Medicaid Drug Rebate Program. Hospital lobbyists call it essential to the safety net. Drug companies call it a loophole. And the basic empirical question of whether those billions in discounts actually reach the low-income patients Congress designed the program to help does not have a clean answer.
It turns out the answer depends heavily on which type of provider you are asking about. The evidence for community health centers tells a very different story than the evidence for hospitals, and that distinction matters enormously for how reform proposals should be evaluated.
We chose this topic in part because a Hill staffer told us directly that decisionmakers need better tools for navigating the 340B debate. That is exactly the kind of signal we want. If there is a health policy debate your office or organization is trying to make sense of, send your suggestions to [email protected].